Xeris Pharmaceuticals Stock Price To Earnings To Growth

XERS Stock

USD 3.36 0.01 0.30%

Xeris Pharmaceuticals fundamentals help investors to digest information that contributes to Xeris Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Xeris Stock. The fundamental analysis module provides a way to measure Xeris Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xeris Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Xeris Pharmaceuticals Company Price To Earnings To Growth Analysis

Xeris Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Xeris Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Xeris Pharmaceuticals is extremely important. It helps to project a fair market value of Xeris Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Xeris Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xeris Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xeris Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Stock	Deferred Long Term Liab	Intangible Assets
Total Assets		0.57	-0.5	0.85	0.85	-0.96	0.8	0.85	0.89	0.9	0.95	0.42	0.93	0.87	0.96	0.56	0.91	-0.81	0.93	0.98	0.93	0.58
Total Stockholder Equity	0.57		0.34	0.51	0.34	-0.53	0.22	0.27	0.66	0.29	0.74	0.62	0.42	0.49	0.74	0.83	0.34	-0.22	0.52	0.42	0.49	-0.02
Net Tangible Assets	-0.5	0.34		-0.37	-0.52	0.52	-0.58	-0.65	-0.27	-0.7	-0.27	0.19	-0.62	-0.42	-0.28	0.2	-0.62	0.76	-0.41	-0.64	-0.46	-0.55
Current Deferred Revenue	0.85	0.51	-0.37		0.9	-0.93	0.85	0.82	0.96	0.85	0.87	0.24	0.88	0.97	0.88	0.61	0.81	-0.68	0.93	0.84	0.85	0.61
Net Debt	0.85	0.34	-0.52	0.9		-0.93	0.97	0.97	0.91	0.95	0.81	0.39	0.95	0.95	0.84	0.49	0.88	-0.83	0.85	0.88	0.81	0.88
Retained Earnings	-0.96	-0.53	0.52	-0.93	-0.93		-0.88	-0.9	-0.95	-0.94	-0.94	-0.37	-0.97	-0.95	-0.95	-0.59	-0.9	0.82	-0.94	-0.96	-0.92	-0.67
Accounts Payable	0.8	0.22	-0.58	0.85	0.97	-0.88		0.94	0.83	0.94	0.73	0.31	0.92	0.89	0.75	0.31	0.8	-0.83	0.78	0.84	0.73	0.89
Net Receivables	0.85	0.27	-0.65	0.82	0.97	-0.9	0.94		0.84	0.97	0.77	0.42	0.96	0.91	0.81	0.45	0.91	-0.92	0.79	0.9	0.78	0.89
Capital Surpluse	0.89	0.66	-0.27	0.96	0.91	-0.95	0.83	0.84		0.85	0.95	0.47	0.91	0.96	0.96	0.75	0.82	-0.69	0.92	0.85	0.87	0.63
Total Liab	0.9	0.29	-0.7	0.85	0.95	-0.94	0.94	0.97	0.85		0.82	0.32	0.99	0.89	0.83	0.42	0.89	-0.91	0.84	0.94	0.84	0.8
Total Current Assets	0.95	0.74	-0.27	0.87	0.81	-0.94	0.73	0.77	0.95	0.82		0.52	0.88	0.88	0.99	0.76	0.83	-0.67	0.93	0.9	0.92	0.49
Short Term Debt	0.42	0.62	0.19	0.24	0.39	-0.37	0.31	0.42	0.47	0.32	0.52		0.36	0.38	0.56	0.61	0.36	-0.37	0.24	0.31	0.25	0.37
Common Stock	0.93	0.42	-0.62	0.88	0.95	-0.97	0.92	0.96	0.91	0.99	0.88	0.36		0.92	0.89	0.52	0.9	-0.88	0.88	0.96	0.89	0.75
Property Plant Equipment	0.87	0.49	-0.42	0.97	0.95	-0.95	0.89	0.91	0.96	0.89	0.88	0.38	0.92		0.91	0.63	0.88	-0.79	0.9	0.86	0.82	0.71
Net Invested Capital	0.96	0.74	-0.28	0.88	0.84	-0.95	0.75	0.81	0.96	0.83	0.99	0.56	0.89	0.91		0.76	0.86	-0.73	0.92	0.9	0.89	0.53
Net Working Capital	0.56	0.83	0.2	0.61	0.49	-0.59	0.31	0.45	0.75	0.42	0.76	0.61	0.52	0.63	0.76		0.49	-0.27	0.61	0.47	0.61	0.19
Long Term Debt	0.91	0.34	-0.62	0.81	0.88	-0.9	0.8	0.91	0.82	0.89	0.83	0.36	0.9	0.88	0.86	0.49		-0.86	0.89	0.95	0.88	0.72
Short Term Investments	-0.81	-0.22	0.76	-0.68	-0.83	0.82	-0.83	-0.92	-0.69	-0.91	-0.67	-0.37	-0.88	-0.79	-0.73	-0.27	-0.86		-0.66	-0.86	-0.64	-0.75
Long Term Debt Total	0.93	0.52	-0.41	0.93	0.85	-0.94	0.78	0.79	0.92	0.84	0.93	0.24	0.88	0.9	0.92	0.61	0.89	-0.66		0.92	0.97	0.55
Capital Stock	0.98	0.42	-0.64	0.84	0.88	-0.96	0.84	0.9	0.85	0.94	0.9	0.31	0.96	0.86	0.9	0.47	0.95	-0.86	0.92		0.94	0.66
Deferred Long Term Liab	0.93	0.49	-0.46	0.85	0.81	-0.92	0.73	0.78	0.87	0.84	0.92	0.25	0.89	0.82	0.89	0.61	0.88	-0.64	0.97	0.94		0.54
Intangible Assets	0.58	-0.02	-0.55	0.61	0.88	-0.67	0.89	0.89	0.63	0.8	0.49	0.37	0.75	0.71	0.53	0.19	0.72	-0.75	0.55	0.66	0.54

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Xeris Pharmaceuticals

Xeris Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.14

At this time, Xeris Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Xeris Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Xeris Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xeris Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics of similar companies.

Xeris Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.

Xeris Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Xeris Pharmaceuticals from analyzing Xeris Pharmaceuticals' financial statements. These drivers represent accounts that assess Xeris Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xeris Pharmaceuticals' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	209.8M	231.5M	180.4M	323.5M	291.2M	305.7M
Enterprise Value	230.6M	307.6M	256.5M	485.3M	436.8M	458.6M

Xeris Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xeris Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xeris Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Xeris Fundamentals

	Return On Equity	-6.17
	Return On Asset	-0.087
	Profit Margin	(0.34) %
	Operating Margin	(0.24) %
	Current Valuation	700.99 M
	Shares Outstanding	149.08 M
	Shares Owned By Insiders	3.92 %
	Shares Owned By Institutions	43.96 %
	Number Of Shares Shorted	9.52 M
	Price To Book	3.34 X
	Price To Sales	2.67 X
	Revenue	163.91 M
	Gross Profit	87.61 M
	EBITDA	(23.73 M)
	Net Income	(62.26 M)
	Cash And Equivalents	111.55 M
	Cash Per Share	0.82 X
	Total Debt	229.19 M
	Debt To Equity	1.87 %
	Current Ratio	2.50 X
	Book Value Per Share	(0.19) X
	Cash Flow From Operations	(47.02 M)
	Short Ratio	5.53 X
	Earnings Per Share	(0.43) X
	Target Price	4.77
	Number Of Employees	377
	Beta	1.29
	Market Capitalization	500.91 M
	Total Asset	322.6 M
	Retained Earnings	(617.02 M)
	Working Capital	61.07 M
	Net Asset	322.6 M

About Xeris Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC